Oncolytics Biotech Inc T.ONC

@CMH or anyone

[pelaboost]

I do not see how today's announcement differs from last year. I do not see any changes in reporting from last year.

As to today's drop, I have no idea. I still think something is in the works for GOBLET and/or PDAC.

Watchng for now.

[pelaboost]

@pelaboost. Very nice call if I do say so myself. One must go to the news release of 11/9/23 to get a feel for what is going on. It appears we have now formalized the GOBLET NEW ARM. PanCAN is still involved and one assumes, by association, GCAR. Patience is required. Very good news.

[CMHarring218431]

Let me be the first to give you an official pat on the back! Onward and Upward! Hopefully, the market will understand the significance and respond with a decent uptick although we are starting in a hole thanks to yesterday. I'm gonna assume yesterday was precipitated by utilizing the ATM one last time before news. Now, onc hold off awhile to let us rise.  GLTA  

[itntdf]

Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, commented, "One of the reasons for pancreatic cancer's poor survival rate is that it effectively evades the immune system and can induce an immunosuppressive tumor microenvironment (TME)2. Pelareorep is an attractive combination partner because of its ability to address both

[ENEMENEMYNEMO]

I believe this is the previously committed 5mil from PanCAN so not yet an endorsement from GCAR.  Trial as1st line PDAC is an acknowledgment....